The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online
doi:10.1084/jem.20062211
The Journal of Experimental Medicine, Vol. 204, No. 2, 253-258
The Rockefeller University Press, 0022-1007 $30.00
© Allakhverdi et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 1535K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allakhverdi, Z.
Right arrow Articles by Delespesse, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allakhverdi, Z.
Right arrow Articles by Delespesse, G.
Right arrowPubmed/NCBI databases
*Protein
*Substance via MeSH
Medline Plus Health Information
*Allergy
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

BRIEF DEFINITIVE REPORT

Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells

Zoulfia Allakhverdi1, Michael R. Comeau4, Heidi K. Jessup4, Bo-Rin Park Yoon4, Avery Brewer4, Suzanne Chartier3, Nicole Paquette3, Steven F. Ziegler5, Marika Sarfati2, and Guy Delespesse1

1 Laboratory on Allergy, 2 Laboratory on Immunoregulation, CHUM Research Center, and 3 Dermatology Service, Notre-Dame Hospital, Montreal, Quebec H2L 4M1, Canada
4 Inflammation Research, Amgen Inc., Seattle, WA 98119
5 Department of Immunology, Benaroya Research Institute, Virginia Mason Medical Center, Seattle, WA 98101

CORRESPONDENCE Guy Delespesse: guy.delespesse{at}sympatico.ca

Compelling evidence suggests that the epithelial cell–derived cytokine thymic stromal lymphopoietin (TSLP) may initiate asthma or atopic dermatitis through a dendritic cell–mediated T helper (Th)2 response. Here, we describe how TSLP might initiate and aggravate allergic inflammation in the absence of T lymphocytes and immunoglobulin E antibodies via the innate immune system. We show that TSLP, synergistically with interleukin 1 and tumor necrosis factor, stimulates the production of high levels of Th2 cytokines by human mast cells (MCs). We next report that TSLP is released by primary epithelial cells in response to certain microbial products, physical injury, or inflammatory cytokines. Direct epithelial cell–mediated, TSLP-dependent activation of MCs may play a central role in "intrinsic" forms of atopic diseases and explain the aggravating role of infection and scratching in these diseases.



Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

TSLP-tickled mast cells
Hema Bashyam
J. Exp. Med. 2007 204: 209. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS